Medication assisted treatment
Methandone
Buprenorphine
Naltrexone
Vivitrol
Opioid treatment program (OTP)
Office based opioid treatment (OBOT)
Drug Addiction Treatment Act (DATA) waiver
Efforts to expand patient access to medication assisted treatment (MAT) for opioid use disorder (OUD) often focus on enhancing the ability of primary care providers and health care clinics to offer MAT treatment. This collection features resources intended to help primary care providers and clinic staff establish and maintain MAT programs for their patients. Continue reading
Despite the overwhelming evidence that medications such as methadone, buprenorphine, and naltrexone are effective at treating opioid use disorder, objections to medication assisted treatment (MAT) are still common. The resources in this collection are intended to help dispell the myths and negative stereotypes about MAT. Continue reading
This collection features resources for state and community leaders interested in implementing medication assisted treatment (MAT) programs for opioid use disorder (OUD) in their communities. Continue reading
This collection provides information about MAT specifically for health care providers. Continue reading
In this featured collection, we put a spotlight on medication assisted treatment (MAT) for opioid use disorder (OUD). Research has proven that MAT is an evidence-based strategy for treating individuals with OUD; individuals who use MAT as part of their treatment and recovery plan are more likely to be retained in treatment and to have fewer adverse events such as opioid overdose and opioid overdose mortality. Continue reading
This collection features resources for patients and caregivers about medication assisted treatment (MAT) for opioid use disorder (OUD), including a guide from Partnership for Drug-Free Kids on MAT for teens and young adults with OUD. Continue reading
This 2019 bulletin describes evidence-based practices for providing medication assisted treatment (MAT) for individuals with opioid use disorder and coverage of these treatment by Virginia’s Medicaid program. Continue reading
This 2019 report from the Urban Institute analyzed Medicaid State Drug Utilization Data to assess variation in buprenorphine prescriptions across state Medicaid programs between 2011 and 2018. Continue reading
In 2017 the Camden Coalition of Healthcare Providers began a pilot in partnership with local addiction treatment providers and UnitedHealthCare to see if removing prior authorization requirements for buprenorphine would reduce barriers to treatment and improve patient and system outcomes. Continue reading
A one and a half hour webinar on best practices in expanding access to buprenorphine in primary care practices from the California Health Care Foundation.
Funding Source: California Health Care Foundation